ArticleInternational journal of molecular sciences2024
DeepEnhancerPPO: An Interpretable Deep Learning Approach for Enhancer Classification.
Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Enhancers are short genomic segments located in non-coding regions of the genome that play a critical role in regulating the expression of target genes. Despite their importance in transcriptional regulation, effective methods for classifying enhancer categories and regulatory strengths remain limited. To address this challenge, we propose a novel end-to-end deep learning architecture named DeepEnhancerPPO. The model integrates ResNet and Transformer modules to extract local, hierarchical, and long-range contextual features. Following feature fusion, we employ Proximal Policy Optimization (PPO), a reinforcement learning technique, to reduce the dimensionality of the fused features, retaining the most relevant features for downstream classification tasks. We evaluate the performance of DeepEnhancerPPO from multiple perspectives, including ablation analysis, independent tests, assessment of PPO's contribution to performance enhancement, and interpretability of the classification results. Each module positively contributes to the overall performance, with ResNet and PPO being the most significant contributors. Overall, DeepEnhancerPPO demonstrates superior performance on independent datasets compared to other models, outperforming the second-best model by 6.7% in accuracy for enhancer category classification. The model consistently ranks among the top five classifiers out of 25 for enhancer strength classification without requiring re-optimization of the hyperparameters and ranks as the second-best when the hyperparameters are refined. This indicates that the DeepEnhancerPPO framework is highly robust for enhancer classification. Additionally, the incorporation of PPO enhances the interpretability of the classification results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.